Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | VCP | P55072 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3640169 | 0.79 | AOC3 (0.44) | AOC3NPC1RAB9AHTR7ADRA1B | |
| SCHEMBL73543 | 0.78 | AOC3 (0.47) | AOC3SLC6A3SLC6A4NPC1RAB9A | |
| SCHEMBL10441226 | 0.77 | AOC3 (0.42) | AOC3NPC1RAB9AHTR7ADRA1B | |
| SCHEMBL3915604 | 0.76 | VCP (0.39) | AOC3SLC6A3SLC6A4NPC1RAB9A | |
| SCHEMBL5584506 | 0.74 | AOC3 (0.40) | AOC3SLC6A3SLC6A4NPC1RAB9A | |
| SCHEMBL5667289 | 0.73 | AOC3 (0.36) | AOC3SLC6A3SLC6A4NPC1RAB9A | |
| SCHEMBL1237690 | 0.72 | MAOB (0.49) | AOC3SLC6A3SLC6A4HRH3HTR7 | |
| SCHEMBL29688552 | 0.72 | MAOB (0.49) | AOC3SLC6A3SLC6A4HRH3HTR7 | |
| SCHEMBL2467564 | 0.71 | HTR2A (0.49) | — | |
| SCHEMBL7968720 | 0.70 | HTR2A (0.47) | AOC3SLC6A3SLC6A4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044136-A1 | Pyridinoylpiperidines As 5-HT1F Agonists | LILLY CO ELI (US) | 2017-02-16 | — | — | US | disclosed |
| US-20150376178-A1 | Pyridinoylpiperidines As 5-HT1F Agonists | ELI LILLY AND COMPANY | 2015-12-31 | — | — | US | disclosed |
| US-8748459-B2 | Pyridinoylpiperidines as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2014-06-10 | — | — | US | disclosed |
| US-8697876-B2 | Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists | COLUCID PHARMACEUTICALS, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20130072524-A1 | Compositions And Methods Of Synthesis Of Pyridinolypiperidine 5-HT1F Agonists | APTUIT (EDINBURGH) LTD. (GB) | 2013-03-21 | — | — | US | disclosed |
| US-20120329820-A1 | Pyridinoylpiperidines As 5-HT1F Agonists | ELI LILLY AND COMPANY (US) | 2012-12-27 | — | — | US | disclosed |
| EP-1626958-B1 | (PIPERIDINYLOXY)PHENYL, (PIPERIDINYLOXY)PYRIDINYL, (PIPERIDINYLSULFANYL)PHENYL AND (PIPERIDINYLSULFANYL)PYRIDINYL COMPOUNDS AS 5-HT 1F AGONISTS | LILLY CO ELI (US) | 2012-06-27 | — | — | EP | disclosed |
| EP-1663971-B1 | SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS | LILLY CO ELI (US) | 2011-12-21 | — | — | EP | disclosed |
| US-8044207-B2 | Pyridinoylpiperidines as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 2011-10-25 | — | — | US | disclosed |
| WO-2011123654-A1 | COMPOSITIONS AND METHODS OF SYNTHESIS OF PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS | COLUCID PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| EP-1663971-A1 | SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS | Eli Lilly and Company (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1626958-A1 | (PIPERIDINYLOXY)PHENYL, (PIPERIDINYLOXY)PYRIDINYL, (PIPERIDINYLSULFANYL)PHENYL AND (PIPERIDINYLSULFANYL)PYRIDINYL COMPOUNDS AS 5-HT 1F AGONISTS | ELI LILLY AND COMPANY (US) | 2006-02-22 | — | — | EP | disclosed |
| US-20050222206-A1 | Pyridinoylpiperidines as 5-ht1f agonists | ELI LILLY AND COMPANY | 2005-10-06 | — | — | US | disclosed |
| WO-2005061439-A1 | SUBSTITUTED (4-AMINOCYCLOHEXEN-1-YL)PHENYL AND (4-AMINOCYCLOHEXEN-1-YL)PYRIDINYL COMPOUNDS AS 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005035499-A1 | SUBSTITUTED 2-CARBONYLAMINO-6-PIPERIDINAMINOPYRIDINES AND SUBSTITUTED 1-CARBONYLAMINO-3-PIPERIDINAMINOBENZENES AS 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2005-04-21 | — | — | WO | disclosed |
| EP-1492786-A1 | PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2005-01-05 | — | — | EP | disclosed |
| WO-2004094380-A1 | (PIPERIDINYLOXY)PHENYL, (PIPERIDINYLOXY)PYRIDINYL, (PIPERIDINYLSULFANYL)PHENYL AND (PIPERIDINYLSULFANYL)PYRIDINYL COMPOUNDS AS 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2003084949-A1 | PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2003-10-16 | — | — | WO | disclosed |
| EP-0071521-B1 | PYRID-3-YL OR PIPERIDIN-3-YL-OXO-2-INDOLE DERIVATIVES, THEIR SALTS, PROCESS FOR THEIR PREPARATION, COMPOSITIONS CONTAINING THEM AND THEIR USES AS MEDICINES | ROUSSEL-UCLAF (FR) | 1985-12-04 | — | — | EP | disclosed |
| EP-0071520-B1 | 3-PIPERIDINYLINDOLE DERIVATIVES, THEIR SALTS AND PREPARATION, THEIR USE IN MEDICINES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1985-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329820-A1 | Pyridinoylpiperidines As 5-HT1F Agonists | HTR1F, HTR1A, HTR1E | AOC3 679/4885SLC6A3 270/4885SLC6A4 64/4885 |
| US-20130072524-A1 | Compositions And Methods Of Synthesis Of Pyridinolypiperidine 5-HT1F Agonists | HTR1F, HTR1A, HTR1D | AOC3 3478/4885SLC6A3 1125/4885SLC6A4 89/4885 |
| US-20170044136-A1 | Pyridinoylpiperidines As 5-HT1F Agonists | HTR1F, HTR1A, HTR1E | AOC3 679/4885SLC6A3 270/4885SLC6A4 64/4885 |
| US-20050222206-A1 | Pyridinoylpiperidines as 5-ht1f agonists | HTR1F, HTR1A, HTR1E | AOC3 679/4885SLC6A3 270/4885SLC6A4 64/4885 |
| US-20150376178-A1 | Pyridinoylpiperidines As 5-HT1F Agonists | HTR1F, HTR1A, HTR1E | AOC3 679/4885SLC6A3 270/4885SLC6A4 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.